Premium
Intralesional interferon‐α for the treatment of bilateral conjunctival mucosa‐associated lymphoid tissue lymphoma
Author(s) -
Holds John,
Buchanan Adam,
Hanson Robin
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23224
Subject(s) - medicine , lymphoma , interferon , treatment modality , alpha interferon , mucosa associated lymphoid tissue , population , lymphatic system , malt lymphoma , pathology , surgery , immunology , environmental health
We describe a case of bilateral conjunctival mucosa‐associated lymphoid tissue (MALT) lymphoma in a 14‐year‐old female treated with intralesional interferon‐α. Interferon‐α‐2b was injected three times a week for 6 weeks, then once weekly for 12 weeks. Marked tumor reduction was observed by week 5 of treatment, with complete resolution by week 8. There was no sign of recurrence through 27 months of follow‐up. Intralesional interferon‐α was an effective treatment for this unusual case of conjunctival MALT lymphoma in a very young female. It presents an attractive alternative to traditional treatment modalities in this patient population. Pediatr Blood Cancer 2012; 59: 176–178. © 2011 Wiley Periodicals, Inc.